Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now

Kenvue reported Q2 revenue of $3.95 billion, up 3% year over year, and EPS of $0.24, up 9%, supported by steady demand for consumer-health brands including Tylenol, Listerine and Band-Aid. Its 4.68% dividend yield and 64-year record of consecutive dividend increases remain key attractions. Kimberly-Clark's proposed acquisition introduces uncertainty around Kenvue's standalone dividend, though the buyer is also a Dividend King with a roughly 5.23% yield and expects scale and cost-saving benefits from the combination.

Analysis

The relevant valuation question is not dividend continuity but whether the transaction consideration adequately compensates KVUE holders for closing risk and litigation overhang. A consumer-health combination offers real procurement, media-spend and distribution synergies, but those benefits accrue primarily to KMB shareholders; KVUE should trade as a merger-arbitrage instrument once the cash/stock mix, collar mechanics and termination provisions are verified. Without those terms, the stated yield is not a useful return anchor.

KMB is the more exposed equity. Funding a large acquisition while defending a high payout can force a choice among leverage, buybacks and post-close dividend growth; any ratings-agency concern or synergy-delay would compress KMB's consumer-staples multiple before it materially changes KVUE standalone earnings. The less obvious risk is that KMB's legacy tissue franchise is relatively mature, so the market may treat the deal as financial engineering unless management can demonstrate revenue synergies rather than relying on cost cuts that may impair brand investment.

Over the next 1-3 months, regulatory filings, financing detail and quantified synergy/dis-synergy targets are the catalysts. Over 6-18 months, the key downside scenario is a prolonged review or remedy requirement, which returns KVUE to a standalone valuation still sensitive to product-liability developments and modest organic-growth expectations. A contrarian outcome is that the deal spread is too narrow: consumer-brand overlap and leverage constraints can create a more meaningful closing-risk discount than income-oriented holders are pricing.

Key Decisions for Investors

• Do not initiate a directional KVUE position solely for yield; wait for the definitive merger agreement, including per-share consideration, stock-exchange ratio/collar and outside date. Treat any position before then as event risk rather than dividend exposure.
• After terms are confirmed, evaluate long KVUE / short KMB at the exact exchange ratio as the preferred expression. Enter only if the annualized gross spread exceeds 10-12% after borrow, dividend and expected-close-date assumptions; exit if regulatory review extends beyond the contractual outside date or the spread fails to compensate for that extension.
• Maintain a negative tactical bias on KMB versus XLP over the next 1-3 months if pro forma net leverage, ratings outlook or dividend-coverage guidance deteriorates. Falsification: credible deleveraging to management's target without a dividend-growth reset, plus synergies large enough to offset incremental interest expense within two years.
• Set an alert around KVUE litigation disclosures and any change in JNJ-related indemnification or reserve language. A material adverse legal development would widen the merger spread and can make a hedged arbitrage position unattractive even if operating results remain stable.